IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by Czech National Bank

Czech National Bank boosted its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 6.5% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,766 shares of the company’s stock after purchasing an additional 1,028 shares during the period. Czech National Bank’s holdings in IDEXX Laboratories were worth $8,471,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Atomi Financial Group Inc. lifted its stake in shares of IDEXX Laboratories by 3.4% in the 1st quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock valued at $344,000 after purchasing an additional 21 shares during the last quarter. Ballentine Partners LLC boosted its stake in IDEXX Laboratories by 1.9% during the first quarter. Ballentine Partners LLC now owns 1,188 shares of the company’s stock worth $641,000 after buying an additional 22 shares during the period. Eads & Heald Wealth Management increased its position in shares of IDEXX Laboratories by 0.8% during the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock valued at $1,309,000 after acquiring an additional 22 shares during the last quarter. LRI Investments LLC raised its stake in shares of IDEXX Laboratories by 21.7% in the 2nd quarter. LRI Investments LLC now owns 129 shares of the company’s stock valued at $63,000 after acquiring an additional 23 shares during the period. Finally, Mather Group LLC. lifted its holdings in shares of IDEXX Laboratories by 4.2% in the 2nd quarter. Mather Group LLC. now owns 594 shares of the company’s stock worth $321,000 after acquiring an additional 24 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of NASDAQ IDXX opened at $477.67 on Friday. The stock’s 50-day simple moving average is $487.95 and its 200-day simple moving average is $495.89. The firm has a market capitalization of $39.45 billion, a PE ratio of 46.24, a price-to-earnings-growth ratio of 4.32 and a beta of 1.33. IDEXX Laboratories, Inc. has a fifty-two week low of $372.50 and a fifty-two week high of $583.39. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37.

IDEXX Laboratories (NASDAQ:IDXX) last released its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the business posted $2.67 EPS. The firm’s revenue for the quarter was up 6.4% compared to the same quarter last year. As a group, equities research analysts forecast that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on the stock. Stifel Nicolaus reduced their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research report on Monday, June 24th. StockNews.com cut shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. BTIG Research began coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price objective on the stock. Finally, Piper Sandler reduced their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research note on Wednesday, August 14th. Three research analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $582.25.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.